Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Combining menin/FLT3/BCL2 inhibition as a treatment approach in FLT3/NPM1 double mutated AML

Michael Andreeff • 20 Mar 2023
ISAL 2023
Acute Myeloid Leukemia Leukemia Gilteritinib Quizartinib Sorafenib Venetoclax

Michael Andreeff, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses ongoing research exploring the possibility of combining BCL2 inhibitors, FLT3 inhibitors and menin inhibitors as a novel treatment approach for patients with FLT3/NPM1 double mutated acute myeloid leukemia (AML). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Andreeff

6:43
Novel mitochondrial targets being explored in AML & strategies to overcome resistance to venetoclax
Michael Andreeff • 20 Mar 2023

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals